Clinical trials: Vascular Conditions
Multiple Myeloma, Multiple Myeloma in Relapse
Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
This is a phase 1, multi-center, single-arm, open-label study evaluating the safety, tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell product) in combination with SEA-BCMA (a monoclonal antibody) in…
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
- Trial name
- NCT03266692
- Testing
- ACTR087, SEA-BCMA
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Cogent Biosciences, Inc.
Critical Limb Ischemia
Stellarex DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries
The purpose is to demonstrate the safety and effectiveness of the Stellarex DCB for the treatment of stenosis or occlusions of below-the-knee arteries.
- Trial name
- ILLUMENATE-BTK (NCT03175744)
- Testing
- Stellarex DCB, PTA Catheter
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 82 people
- Sponsor
- Spectranetics Corporation
Acute Myocardial Infarction
SpinChip Hs-cTnI Sample Type Validation
During a heart attack, the protein troponin I is released from the heart muscle into the bloodstream. Measurements of cardiac troponin in blood are used as an aid in the diagnosis of heart attack.
- Trial name
- HEAT-2 (NCT06453707)
- Testing
- SpinChip hs-cTnI
- Where
- Norway
- Volunteers
- 180 people
- Sponsor
- SpinChip Diagnostics ASA
Myocardial Infarction, Sudden Death
Clinical Registry on Sudden Death Primary Prevention at Latin America
INTRODUCTION: Sudden cardiac death is one of the most important reasons of death at industrialized countries. Despite its importance, nowadays Clinical Guidelines are not as extended as expected, with respect to indications for…
- Trial name
- ESCAPE-ICD (NCT01422174)
- Testing
- Implantable Cardio Defibrillator (ICD),
- Where
- Argentina
- Sponsor
- Biotronik SE & Co. KG
Stroke, Cerebral Ischemia
ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.
- Conditions
- Stroke, Cerebral Ischemia, Brain Infarction
- Trial name
- NCT00300196
- Testing
- Ancrod (Viprinex)
- Where
- 94 sites in United States, Australia and 9 more
- Volunteers
- 311 people
- Sponsor
- Neurobiological Technologies
Pulmonary Hypertension, Interstitial Lung Disease
Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease
This is an Expanded Access Program (EAP) for eligible participants with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) designed to provide access to Inhaled Treprostinil.
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Trial name
- NCT05572996
- Testing
- Inhaled Treprostinil
- Sponsor
- Ferrer Internacional S.A.
Atrial Fibrillation, Venous Thromboembolism
Edoxaban Management in Diagnostic and Therapeutic Procedures
Patients receiving Novel Oral Anticoagulation (NOACs) undergo diagnostic and therapeutic procedures at a rate of 10% per year. Short half-lives and rapid onset of action allow for short periods of NOAC interruption without…
- Trial name
- EMIT-AF/VTE (NCT02950168)
- Testing
- Edoxaban
- Volunteers
- 1,197 people
- Sponsor
- Daiichi Sankyo
Ischemic Heart Disease, Stable Coronary Artery Disease
To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent
to evaluate safety and efficacy of CGBIO stent(DES) compared to Biomatrix flex stent(DES)
- Conditions
- Ischemic Heart Disease, Stable Coronary Artery Disease, Stable Angina, Unstable Angina
- Trial name
- NCT03089450
- Testing
- CGBio stent, Biomatrix flex
- Where
- South Korea
- Volunteers
- 112 people
- Sponsor
- CGBio Inc.
STEMI
STENTYS Self-expanding Versus Balloon-expandable Stent in Acute Myocardial Infarction (AMI)
Study hypothesis: the Stentys self-expandable Stent results into a better alignment of the struts to the vessel wall than a balloon-expandable stent within a few days after the procedure in acute myocardial infarction patients.
- Trial name
- APPOSITION ll (NCT01008085)
- Testing
- Stentys coronary stent, Balloon-expandable stent
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Stentys
Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world…
- Conditions
- Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphoma
- Trial name
- ARIADNE (NCT05326308)
- Testing
- Zanubrutinib, Obinutuzumab
- Where
- 2 sites in Austria, Germany
- Volunteers
- 845 people
- Sponsor
- iOMEDICO AG
Diabetic Retinopathy, Low Vision
Diabetic Retinopathy Tethered Augmented Reality With Eye4 Study
Diabetes has reached epidemic levels in North America and with it, diabetic retinopathy is increasingly affecting the vision of millions of people.
- Trial name
- DRTARES (NCT05491746)
- Testing
- Eye4
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Eyedaptic
STEMI - ST Elevation Myocardial Infarction, Anterior MI
Observational Registry to Evaluate Real World Usage of PiCSO Impulse System in STEMI Patients as Part of Post-marketing Surveillance
A prospective, multicenter, single-arm, open label registry of commercially treated patients with PiCSO Impulse System.
- Trial name
- PiCSO-AMI-IV (NCT04566289)
- Testing
- PiCSO
- Where
- Germany
- Sponsor
- Miracor Medical SA
Venous Thromboembolism
Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism
The study objective is to evaluate the efficacy and safety of oral YM150 for 52 weeks in patients with a history of venous thromboembolism.
- Trial name
- NCT00937820
- Testing
- YM150
- Where
- 5 sites in Japan
- Volunteers
- 87 people
- Sponsor
- Astellas Pharma Inc
Chronic Kidney Failure, Vascular Graft Occlusion
A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis
The study will look at the safety profile (unwanted effects) of the long-lasting anticoagulant PEG-hirudin (SPP200) and compare these unwanted effects to those of unfractionated heparin, commonly used in haemodialysis to avoid…
- Trial name
- NCT00074620
- Testing
- PEG-hirudin
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Speedel Pharma Ltd.
Stroke, Atrial Fibrillation
Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation
This study is to demonstrate the safety and efficacy profile, in two different dose regimens of Edoxaban (DU-176b), (an investigational new drug being tested for the prevention of stroke/systemic embolic events (SEE)), in…
- Conditions
- Stroke, Atrial Fibrillation, Embolism
- Trial name
- EngageAFTIMI48 (NCT00781391)
- Testing
- warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg)
- Where
- 1,009 sites in United States, Argentina and 44 more
- Volunteers
- 21,105 people
- Sponsor
- Daiichi Sankyo
Intermittent Claudication, Peripheral Artery Disease
A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication
The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with peripheral artery disease and…
- Trial name
- NCT01131013
- Testing
- 375 mg CK-2017357, 500 mg CK-2017357
- Where
- 14 sites in United States
- Volunteers
- 61 people
- Sponsor
- Cytokinetics
Ischemic Attack, Transient
Cognitive and Physical Functions in Patients With Transient Ischemic Attack. A Randomized Controlled Trial of Physical Activity on Prescription up to One Year After the Event
The purpose of this study is to determine whether Physical Activation on Prescription can help patients with TIA to become more physically active.
- Trial name
- NCT01509924
- Testing
- Physical activation on Prescription
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Tiohundra AB
Atrial Fibrillation, Stroke
Using Left Atrium Appendage Closure in NVAF Patients With High Risk of Ischemic Stroke
To evaluate the safety and efficacy of using Microport CardioAdvance Left Atrium Appendage Closure for preventing stroke in Non-valvular atrial fibrillation (NVAF) patients who have contraindications for long-term…
- Trial name
- SAFE-PROTECT (NCT04479722)
- Testing
- Left atrial appendage closure procedure
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease, Left Ventricular Dysfunction
DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation
This trial is a prospective, multi-center, randomized study of patients with coronary artery disease (CAD) and mild to moderate left ventricular (LV) dysfunction.
- Conditions
- Coronary Artery Disease, Left Ventricular Dysfunction, Sudden Cardiac Death
- Trial name
- DETERMINE (NCT00487279)
- Testing
- Defibrillator, Control
- Where
- 56 sites in United States
- Volunteers
- 81 people
- Sponsor
- Abbott Medical Devices
Angina, Coronary Occlusion
XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
The objectives of the PMS are to observe the frequency, type, and degree of device deficiency to assure the safety of the new medical device (XIENCE PRIME) as well as to collect information on evaluation of the efficacy and…
- Conditions
- Angina, Coronary Occlusion, Coronary Artery Disease, Coronary Artery Stenosis
- Trial name
- NCT01721096
- Testing
- XIENCE PRIME - Long Length (LL), XIENCE PRIME - Core Size
- Where
- Japan
- Volunteers
- 536 people
- Sponsor
- Abbott Medical Devices
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.